SHL Medical welcomes Lyophilization Technology, Inc.

Within its alliance partnership framework, SHL Medical, a world-leading solutions provider of advanced drug delivery systems has entered a non-exclusive strategic partnership with Lyophilization Technology, Inc. (hereafter “LTI”), a contract development and manufacturing organization (CDMO) specializing in lyophilization for preparation of health care products.

Lyophilization is increasingly used in the development of injectable drugs to enhance their shelf life and thermal stability. Traditionally, lyophilized medications were delivered via individual vials of product and diluent that often require healthcare professionals to administer, or complex kits for self administration. With Reunite^TM, SHL Medical recently introduced a dual-chamber cartridge autoinjector supporting automated reconstitution that facilitates the delivery of lyophilized formulations. It features a simple three-step process ensuring accurate dosing with a user-friendly design for safe and effortless self-administration. Reduced contamination potential and increased patient compliance are additional benefits.LTI brings deep expertise in lyophilization, coupled with proven capabilities in product development and process engineering, and preparing dual-chamber cartridges for clinical studies in full compliance with both US and EU regulatory standards.

As the pharmaceutical industry sees a growing demand for patient-friendly administration of lyophilized injectable drugs, SHL Medical and LTI are joining forces to deliver solutions that meet the evolving needs of drug developers. By combining SHL’s new autoinjector platform with LTI’s development capabilities for dual-chamber cartridges, the partnership enables the efficient production of clinical-grade material.

Ralph Howald, SHL Medical’s CTO, commented: “We are excited to partner with Lyophilization Technology, Inc. to further support our customers during the critical and complex phases of feasibility assessments and clinical studies. This collaboration creates meaningful synergies that drive drug delivery innovation, streamline development timelines, and support the advancement of therapies that improve patient outcomes.”

“We value the collaboration with SHL as an industry leader, having a shared vision of providing an effective and economical pathway in developing new product innovations,” said Ed Trappler, President of Lyophilization Technology, Inc. “This provides unique opportunities for delivering life-changing therapies in home healthcare, being safe, effective, and most comfortable to the patient.”

About SHL Medical 

As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients’ Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems.  ​ 

Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical’s global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. 

​For additional information, visit http://www.shl-medical.com/

Media contact: [email protected]

About Lyophilization Technology, Inc.

Lyophilization Technology, Inc. (LTI) is a premier CDMO focused exclusively on lyophilization for healthcare products. LTI offers a comprehensive suite of services, including product and process development, clinical trial manufacturing, and technical services. The range of services includes product design, formulation development, process engineering and technical consulting. This includes working with conventional primary packaging as well as dual-chamber presentations.

Capabilities include small and large molecules, potent-material containment, seamless clinical trial material manufacturing and technical support for integrating a product and process into commercial manufacturing.  LTI delivers innovative and client-focused solutions, overcoming the most demanding scientific and technical challenges.  With a commitment to innovation and patient-centric solutions, LTI partners with pharmaceutical and biotechnology companies to bring complex therapies to life.

For additional information, visit www.lyotechnology.com

SHL Medical 
Media contact
Christine Mueller
Corporate Communications
[email protected]
+41 41 368 00 00 

Lyophilization Technology, Inc.
Media contact
Robert Cashman
VP, Business Development
[email protected]
215-396-8373